Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon

Looking to the future: How can emerging therapeutic options influence the management landscape?

Date

14 Sep 2020

Session

Janssen - Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon

Presenters

Benjamin Besse

Authors

L.V. Sequist1, B. Besse2

Author affiliations

  • 1 Cancer Center, Massachusetts General Hospital, 02114 - Boston/US
  • 2 Dept Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings